Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours Β· Estimated delivery Oct 10 - Oct 15
Its unique profile (native gastric peptide, stable without carriers, effective at nanogram doses, modulating multiple interconnected neurotransmitter systems simultaneously, promoting actual neuronal repair rather than just symptomatic relief) distinguishes it from all existing psychiatric medications
As a first-in-class triple agonist, its adverse event profile is of particular interest to researchers because the glucagon receptor component adds a mechanism not present in existing dual-agonist compounds like tirzepatide
Furthermore, during acute kidney injury (AKI), studies show that T cells in the kidney have poor fatty acid oxidation and significant glycolytic activity
The logic is that more frequent, smaller doses create a more stable blood level of tirzepatide throughout the week, potentially reducing side effects further while maintaining more consistent receptor activation
As of April 2026, GHK-Cu, glutathione, and ascorbic acid do not appear on the FDA's list of bulk drug substances that may not be used in compounding (the 503A "negative list")
